Abiopharma

🔍 Nolan Sean P. (Executive)

Company: Taysha Gene Therapies, Inc. (TSHA)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Acquired 1,008,000 shares of Common Stock (Direct)
  Date: 2026-01-12 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,086,358.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-12 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 1,535,545.00 | Footnotes: F2
• Acquired 648,000 shares of Employee Stock Option (right to buy) at $4.86 per share (Derivative)
  Date: 2026-01-12 | Code: A | Expires: 2036-01-12 | equity_swap_involved: 0 | shares_owned_after: 648,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
• F2: The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
• F3: 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.